JAMA Psychiatry | Original Investigation

Polygenic Risk of Psychosis and Ventral Striatal Activation During Reward Processing in Healthy Adolescents

Thomas M. Lancaster, PhD; David E. Linden, MD, PhD; Katherine E. Tansey, PhD; Tobias Banaschewski, MD, PhD; Arun L. W. Bokde, PhD; Uli Bromberg, Dipl-Psych; Christian Büchel, MD; Anna Cattrell, PhD; Patricia J. Conrod, PhD; Herta Flor, PhD; Vincent Frouin, PhD; Jürgen Gallinat, MD; Hugh Garavan, PhD; Penny Gowland, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot, MD, PhD; Marie-Laure Paillère Martinot, MD, PhD; Eric Artiges, MD, PhD; Herve Lemaitre, PhD; Frauke Nees, PhD; Dimitri Papadopoulos Orfanos, PhD; Tomáš Paus, MD, PhD; Luise Poustka, MD; Michael N. Smolka, MD; Nora C. Vetter, PhD; Sarah Jurk, Dipl-Psych; Eva Mennigen, MD; Henrik Walter, MD, PhD; Robert Whelan, PhD; Gunter Schumann, MD; for the IMAGEN Consortium

IMPORTANCE Psychotic disorders are characterized by attenuated activity in the brain's valuation system in key reward processing areas, such as the ventral striatum (VS), as measured with functional magnetic resonance imaging.

OBJECTIVE To examine whether common risk variants for psychosis are associated with individual variation in the VS.

DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study of a large cohort of adolescents from the IMAGEN study (a European multicenter study of reinforcement sensitivity in adolescents) was performed from March 1, 2008, through December 31, 2011. Data analysis was conducted from October 1, 2015, to January 9, 2016. Polygenic risk profile scores (RPSs) for psychosis were generated for 1841 healthy adolescents. Sample size and characteristics varied across regression analyses, depending on mutual information available (N = 1524-1836).

MAIN OUTCOMES AND MEASURES Reward-related brain function was assessed with blood oxygen level dependency (BOLD) in the VS using the monetary incentive delay (MID) task, distinguishing reward anticipation and receipt. Behavioral impulsivity, IQ, MID task performance, and VS BOLD were regressed against psychosis RPS at 4 progressive *P* thresholds ($P < .01$, $P < .05$, $P < .10$, and $P < .50$ for RPS models 1-4, respectively).

RESULTS In a sample of 1841 healthy adolescents (mean age, 14.5 years; 906 boys and 935 girls), we replicated an association between increasing psychosis RPS and reduced IQ (matrix reasoning: corrected $P = .003$ for RPS model 2, 0.4% variance explained), supporting the validity of the psychosis RPS models. We also found a nominally significant association between increased psychosis RPS and reduced MID task performance (uncorrected $P = .03$ for RPS model 4, 0.2% variance explained). Our main finding was a positive association between psychosis RPS and VS BOLD during reward anticipation at all 4 psychosis RPS models and for 2 *P* thresholds for reward receipt (RPS models 1 and 3), correcting for the familywise error rate (0.8%-1.9% variance explained).

CONCLUSIONS AND RELEVANCE These findings support an association between psychosis RPS and VS BOLD in adolescents. Genetic risk for psychosis may shape an individual's response to rewarding stimuli.

Editorial page 777

Supplemental content at jamapsychiatry.com

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The other IMAGEN Consortium members are listed at the end of this article.

Corresponding Author: Thomas M. Lancaster, PhD, Neuroscience and Mental Health Research Institute, Hadyn Ellis Bldg, Maindy Road, Cardiff University, Cardiff CF24 4HQ, United Kingdom (lancastertm@cardiff.ac.uk).

JAMA Psychiatry. 2016;73(8):852-861. doi:10.1001/jamapsychiatry.2016.1135
Published online July 6, 2016. Last corrected on August 22, 2016.

Psychotic disorders share considerable genetic variance[1,2] and have considerable overlap in the clinical phenotype.[3] There is thus increasing interest in biological and psychological mechanisms that may operate across these disorders. Attempts to unify mechanisms in psychosis use methods such as magnetic resonance imaging (MRI) to explore the neural circuits that are disrupted in psychosis.[4-6] Psychosis is characterized by changes in reward valuation systems and underlying frontostriatal circuitry.[7-11] A recent meta-analysis[12] suggests that psychosis is associated with alterations in ventral striatal (VS) blood oxygen level dependency (BOLD), suggesting that VS BOLD during reward processing may be a candidate mechanism by which psychosis susceptibility manifests. This hypothesis is also supported by associations between VS BOLD and negative symptoms (see the meta-analysis by Radua et al[12]). Studies have further found that reward processing is heritable[13] and altered in relatives of patients with psychosis,[14] suggesting that genetic risk may contribute to VS BOLD.

Individual genetic risk loci confer small amounts of susceptibility[1]; however, risk profile scores (RPSs) explain larger proportions of variance for psychosis and can be used to predict variance in related phenotypes.[1] We recently found that a schizophrenia RPS was associated with an attenuated VS BOLD response during a probabilistic learning task,[15] suggesting that the cumulative effect of risk single-nucleotide polymorphisms was associated with the VS BOLD alterations previously observed in patients with psychosis[16-18] and unaffected relatives.[19] However, it is currently not known whether polygenic risk of psychotic disorders is associated with reward processes, such as anticipation and receipt, as assayed using the monetary incentive delay (MID) task.[20] The MID task assays BOLD during incentive processing and is relatively independent of reward-based learning (participants learn the stimulus-reward associations before scanning)[21] compared with probabilistic learning paradigms, which assay an individual's ability to dynamically update assumptions based on choice behavior and outcomes.[15,22] The putative absence of a learning component within the MID paradigm will address whether the psychosis RPS is associated with affective salience toward reward. To answer this question, we used the IMAGEN[23] cohort (http://www.imagen-europe.com/) to probe VS BOLD for associations with the psychosis RPS. We initially assayed the psychosis RPS rather than schizophrenia and bipolar summary data sets because (1) in a sample of healthy adolescents, we replicated an association between increasing psychosis RPS and reduced IQ[12]; (2) we hypothesize that VS BOLD will be linked to the genetic risk that is shared between schizophrenia and bipolar disorder; (3) we aimed to reduce the number of RPS comparisons; and (4) recent success has linked psychosis RPS to other imaging phenotypes.[24]

On the basis of a previous meta-analysis,[12] we anticipated that the psychosis RPS would be associated with reductions in VS BOLD during reward anticipation in the MID task and to a lesser extent during reward receipt, mirroring the findings in people with manifest psychosis.[12] We also used a psychosis RPS approach to probe for putative association with (1) intelligence using the Wechsler Intelligence Scale for Children–Fourth Edition (WISC-IV),[25] (2) behavioral impulsivity using a delay discounting paradigm,[26] and (3) MID task performance. We assay intelligence to ensure that the putative psychosis RPS effects on reward are independent of intelligence. The delay discounting paradigm quantifies an individual's ability to delay gratification, a phenotype that is heritable[27] and altered in psychosis.[28,29] Using a psychosis RPS approach, we sought to determine whether psychosis RPS was associated with these phenotypes. Together, we anticipate that these regressions will help elucidate how common risk for psychosis may affect reward systems in the adolescent brain.

Key Points

Question Do common genetic risk alleles for psychosis contribute to reward processing in adolescents?

Findings In a study of the IMAGEN cohort of 1528 adolescents, common genetic risk alleles for psychosis explain approximately 1% to 2% of the variance in reward processing in the ventral striatum (as measured using functional magnetic resonance imaging).

Meaning Common genetic risk for psychosis may shape an individual's response to rewarding stimuli.

Methods

Participants

We analyzed data from the IMAGEN project, a well-characterized, European, multicenter, genetic-neuroimaging study in adolescence[23] (**Table 1**). Participants were recruited from March 1, 2008, through December 31, 2011, through secondary schools at 8 sites located in England, France, Ireland, and Germany. Data analysis was conducted from October 1, 2015, to January 9, 2016. The IMAGEN project had obtained ethical approval by the local ethics committees and written informed consent from all participants and their legal guardians. Standard operating procedures for IMAGEN are available at http://www.imagen-europe.com/en/Publications_and_SOP.php. All individuals were screened for magnetic resonance contraindications and medical conditions. All participants were assessed for psychopathologic conditions as part of a scale tailored to adolescents and based on *International Statistical Classification of Diseases, 10th Revision* (*ICD-10*), as well as *DSM-IV* (Development and Well-Being Assessment Interview). Participants were excluded based on the presence of schizophrenia or bipolar disorder, neurodevelopmental disorders (such as autism), or an IQ of less than 70 (for further exclusion criteria, see the Supplement in the article by Schumann et al[23]).

Genetic Data

To ensure high quality and sufficient quantity, we semiautomated DNA extraction.[8] The Illumina Quad 610 chip (Illumina Inc) was used for genome-wide genotyping of approximately 600 000 autosomal single-nucleotide polymorphisms.

As part of the IMAGEN project, DNA was extracted from blood samples. Genotyping methods and quality control de-

Table 1. Sample Size for Each Psychosis Risk Profile Score Regression Analysis

Variable	Sample Size, No.	Age, Mean (SD), y	Male/Female, No.	Mean (SD) Finding
IQ (WISC-IV)				
Block design	1835	14.52 (0.90)	903/932	50.51 (9.51)
Vocabulary	1833	14.52 (0.90)	902/931	49.87 (8.46)
Matrix reasoning	1835	14.52 (0.90)	903/932	26.41 (4.03)
Similarities	1836	14.52 (0.90)	903/933	30.39 (5.59)
Reward (behavior)				
Delay discounting (log *k*)	1822	14.52 (0.90)	927/895	−1.88 (0.61)
MID (No. of successful trials, maximum of 22 per reward level)	1732	14.51 (0.92)	856/876	13.76 (1.95)
MID (No. of early responses)	1737	14.51 (0.91)	857/880	0.11 (0.1)
Reward (fMRI)				
Anticipation	1528	14.56 (0.45)	740/788	NA
Receipt	1559	14.56 (0.45)	769/790	NA

Abbreviations: fMRI, functional magnetic resonance imaging; MID, monetary incentive delay; NA, not applicable; WISC-IV, Wechsler Intelligence Scale for Children–Fourth Edition.

tails can be found in the eMethods in the Supplement. After quality control, 502 160 single-nucleotide polymorphisms were considered for the psychosis RPS score calculation in 1841 individuals (for whom demographic data were also available).

Generation of RPSs

Psychosis RPSs were calculated using the method described by the International Schizophrenia Consortium.[30] Psychosis genetic risk was estimated using publicly available results data from an international genome-wide association study of 19 779 patients with psychosis and 19 423 controls.[1] For a description of the methods used to calculate the psychosis RPSs and the characteristics of the psychosis RPSs in the sample, see the eMethods and eFigure 1 in the Supplement. In a post hoc analysis, we estimated RPSs for schizophrenia and bipolar disorder separately using available summary statistics for schizophrenia and bipolar generated by the Cross-Disorder Group of the Psychiatric Genomics Consortium.[31]

Intelligence, Behavioral Impulsivity, and Psychopathology

We measured IQs using the WISC-IV.[25] We tested psychosis RPSs against 4 parameters (similarities, vocabulary, block design, matrix reasoning) and used them as covariates to control for potential confounding IQ effects in the psychosis RPS regressions on reward function (delay discounting, behavioral MID, reward anticipation, and receipt). Delay discounting was measured with the questionnaire designed by Kirby and Maraković,[26,32] using a series of 27 choices between a hypothetic smaller, sooner and a larger, later reward. We computed a subjective discount parameter (*k*) as previously described.[29] The *k* values were log transformed before the analyses to account for a skewed distribution. Because VS BOLD has been associated with other phenotypes, such as depressive symptoms[33] and smoking behavior,[34] we additionally screened for depressive symptoms (which were rated using the Development and Well-Being Assessment Interview with a computerized diagnostic algorithm that predicts the likelihood of a clinical diagnostic rating[35]) and smoking behavior (measured using the Fagerström Test for Nicotine Dependence[36]).

Monetary Incentive Delay MRI Task

Participants performed a modified version of the MID task[20,37] during scanning. Details of the paradigm are detailed in the eMethods in the Supplement.

MRI Data Acquisition and Preprocessing

Images were processed as previously described by IMAGEN consortium[23] (eMethods in the Supplement). Because of our a priori hypotheses of associations between psychosis RPS and VS BOLD, which is consistently recruitment during the MID task,[34,38] we tested our hypothesis solely in this region of interest. The VS masks were composed of 9-mm spheres centered at the x, y, and z values of −14, 8, and −8 and 14, 8, and −8, respectively (Montreal Neurological Institute coordinates), for the left and right VS as previously described.[21,38]

Power Analysis

Using the methods outlined by Dudbridge,[39] we had 80% power to detect an effect ranging from 0.044% to 0.052% explained variance (eMethods in the Supplement).

Statistical Analysis

We ran multiple regression for the 4 WISC-IV variables, delay discounting in R version 3.0.2 (https://cran.r-project.org/), where the log-transformed hyperbolic discounts (log *k*) function as the dependent variables and psychosis RPS as the independent variable at 4 progressive *P* thresholds ($P < .05$ for RPS model 1, $P < .05$ for RPS model 2, $P < .10$ for RPS model 3, and $P < .50$ for RPS model 4). These progressive *P* thresholds explain the most variance in the clinical phenotype.[1] We correct for the number of multiple comparisons across *P* thresholds using the false discovery rate. Each regression was controlled for age, sex, testing site, IQ (measured by the 4 WISC-IV variables), and the first 5 principle components (from the variance-standardized relationship matrix of the linkage disequilibrium–pruned genotypes) to account for ancestry admixture (population stratification) and potential relatedness.[40] We repeated these regressions (using the same covariates as the delay discounting regression) for the MID task performance (as measured by number of successful attempts

Table 2. Associations Between Psychosis RPS and WISC-IV Variables[a]

WISC-IV Variable and Psychosis RPS Model	R^2	β	*P* Value
Block design (n = 1835)			
RPS model 1	0.0017	−0.05	.04
RPS model 2	0.0020	−0.06	.03
RPS model 3	0.0029	−0.05	**.01**
RPS model 4	0.0019	−0.05	.03
Vocabulary (n = 1833)			
RPS model 1	−0.0005	−0.008	.75
RPS model 2	−0.0005	0.007	.90
RPS model 3	−0.0005	−0.003	.77
RPS model 4	−0.0001	0.02	.38
Matrix reasoning (n = 1835)			
RPS model 1	0.0035	−0.06	**.006**
RPS model 2	0.0042	−0.06	**.003**
RPS model 3	0.0034	−0.07	**.007**
RPS model 4	0.0024	−0.05	.02
Similarities (n = 1836)			
RPS model 1	0.0003	−0.03	.21
RPS model 2	−0.0005	0.009	.88
RPS model 3	−0.0005	0.004	.70
RPS model 4	0.0000	0.02	.30
Log K (n = 1822)			
RPS model 1	−0.0003	0.02	.46
RPS model 2	−0.0002	0.02	.40
RPS model 3	−0.0005	0.001	.96
RPS model 4	−0.0005	0.004	.86

Abbreviations: RPS, risk profile score; WISC-IV, Wechsler Intelligence Scale for Children–Fourth Edition.

[a] Associations were adjusted for age, sex, testing site, and the first 5 principal components. The log κ values were adjusted for the same covariates and the 4 WISC-IV variables. Associations that survive correction for multiple comparisons (false discovery rate) are in bold.

Table 3. Associations Between Psychosis RPS and Behavioral Performance in the MID Task

MID Task and Psychosis RPS Model	R^2	β	*P* Value
Success (n = 1732)			
RPS model 1	−0.00015	−0.02	.39
RPS model 2	0.00002	−0.02	.31
RPS model 3	0.00089	−0.04	.11
RPS model 4	0.00204	−0.05	.03
Early responses (n = 1737)			
RPS model 1	−0.00057	−0.003	.89
RPS model 2	0.00036	0.03	.20
RPS model 3	0.00182	0.05	.04
RPS model 4	0.00270	0.06	.02

Abbreviations: MID, monetary incentive delay; RPS, risk profile score.

to obtain reward and proportion of early responses) and in the neuroimaging data, using SPM8 software (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/), where the dependent variables were VS BOLD during reward anticipation and receipt. We controlled for multiple testing across the VS search space using familywise error correction ($P < .05$).

Results

Psychosis RPS and IQ

We found nominally significant negative associations between the psychosis RPS and WISC-IV variables (uncorrected block design and corrected matrix reasoning) across all *P* thresholds. No associations were found between psychosis RPS and delay discounting when controlling for age, sex, testing site, WISC-IV variables, and the first 5 principle components (**Table 2**).

Psychosis RPS and MID Task Performance

We found a nominally significant association between the psychosis RPS and behavioral performance in the MID task. The psychosis RPS was negatively associated with the number of successful attempts and an increased proportion of early responses, explaining 0.18% to 0.27% of the variance, after adjusting for covariates (**Table 3**).

Table 4. Significant Voxel Clusters From the Psychosis RPS Regression During Reward Anticipation and Receipt, Controlling for Covariates, Across 4 Progressive *P* Thresholds

P Threshold	κ	MNI Coordinates (x, y, z)	*z*	Familywise Error *P*	R^2	β
Reward anticipation						
RPS model 1	7	−12,2, −8	3.91	.01	0.008	0.10
RPS model 2	11	−12,2, −8	4.70	.001	0.019	0.14
RPS model 3	11	−18,1, −8	4.48	.001	0.017	0.14
RPS model 4	6	−18,2, −5	3.95	.009	0.013	0.12
Reward receipt						
RPS model 1	NA	NA	NA	NA	NA	NA
RPS model 2	1	−9,5, −8	3.33	.05	0.010	0.10
RPS model 3	NA	NA	NA	NA	NA	NA
RPS model 4	3	−18, −1, −8	3.61	.02	0.009	0.10

Abbreviations: κ, number of contiguous voxels; MNI, Montreal Neurological Institute; NA, not applicable; RPS, risk profile score.

Group Effects of Reward Anticipation and Receipt

Whole group (1-sample *t* test) effects are documented in eFigure 2 and the eResults in the Supplement.

Psychosis RPS and Reward Anticipation

We found a positive association between psychosis RPS and VS BOLD at all 4 thresholds (**Table 4** and **Figure**, A). No negative associations were found between the psychosis RPS and VS BOLD after controlling for the familywise error across the VS region of interest. To explore the effects of extreme polygeneticity (comparing individuals with the highest psychosis RPS and individuals with the lowest psychosis RPS), we split the whole sample into 10 deciles (as previous described[41]) and explored the difference between decile 1 (lowest polygenic risk) and decile 10 (highest polygenic risk) for parameter estimates extracted from the significant clusters (Cohen *d* = 0.43; 95% CI, 0.203-0.658, for RPS model 1; Cohen *d* = 0.476; 95% CI, 0.248-0.703, for RPS model 2; Cohen *d* = 0.492; 95% CI, 0.264-0.72, for RPS model 3; and Cohen *d* = 0.438; 95% CI, 0.21-0.665, for RPS model 4). All effects were significant after controlling for comparisons among the 10 deciles (corrected *P* < .001 in all cases).

Psychosis RPS and Reward Receipt

We found a positive association between the psychosis RPS and VS BOLD for RPS models 1 and 3 (Table 4 and Figure, B). No negative associations were found between the psychosis RPS and VS BOLD after controlling for the familywise error across the VS region of interest. We split the whole sample into 10 deciles and looked at the differences between decile 1 (lowest polygenic risk) and decile 10 (highest polygenic risk) for parameter estimates extracted from the significant clusters (Cohen *d* = 0.395; 95% CI, 0.171-0.62, for RPS model 1; Cohen *d* = 0.227; 95% CI, 0.004-0.45, for RPS model 3); however. only the effect identified at the RPS model 1 threshold remained significant after correcting for multiple comparisons (corrected *P* = .007).

Depressive Symptoms and Smoking Behavior

A positive association was found between psychosis RPS and number of depressive symptoms ($t_{9,1817}$ = 2.965, *P* = .003, for RPS model 4). However, no associations were found between depressive symptoms and the 6 VS BOLD parameter estimates (*P* > .40 in all cases), and the association between the psychosis RPS and VS BOLD did not significantly change after controlling for depressive symptoms. No association was found with smoking behavior and (1) the psychosis RPS (*P* > .30 in all cases) and (2) the 6 VS BOLD parameter estimates (*P* > .10 in all cases).

Contribution of Schizophrenia and Bipolar to Psychosis RPS Effects

The association between the psychosis RPS and WISC-IV variables (block design and matrix reasoning) was driven exclusively by the schizophrenia RPS. We did not observe a specific effect of the schizophrenia or bipolar RPS on MID task performance (success and reaction time). However, VS BOLD was influenced by schizophrenia and bipolar RPS (eResults and eTable in the Supplement).

Discussion

We observed and replicated associations between the psychosis RPS and reduced performance IQ,[42-44] supporting the validity of the psychosis RPS approach. Post hoc analysis revealed that this association was driven by the schizophrenia RPS. Additional support for the psychosis RPS model came from evidence supporting an association between the psychosis RPS and task performance during the MID task, although this association did not withstand correction for multiple comparisons, and we could not find a specific contribution from the schizophrenia or bipolar RPS. We also did not observe an association between the psychosis RPS and behavioral impulsivity, as measured using a delay discounting paradigm. Consistent with our main hypothesis, we observed an association between the psychosis RPS and VS BOLD. Consistent with our original hypothesis, the association between the psychosis RPS and VS BOLD was driven by the RPS for schizophrenia and bipolar disorder. These findings support previous associations between common psychosis risk loci (*ODZ4*, *CACNA1C*) and reward processing.[45,46] Furthermore, we build on previous

Figure. Coronal Sections at Montreal Neurological Institute Coordinate y = 5



Positive associations between the psychosis risk profile score (RPS) and blood oxygen level dependency (BOLD) in the ventral striatum (VS) during reward anticipation and reward receipt at 4 progressive *P* thresholds (*P* < .01 for RPS model 1, *P* < .05 for RPS model 2, *P* < .10 for RPS model 3, and *P* < .50 for RPS model 4), controlling for age, sex, testing site, Wechsler Intelligence Scale for Children–Fourth Edition variables, and the first 5 principal components (n = 1528 and 1559, respectively). All clusters are corrected for the familywise error across the bilateral VS (*P* < .05). Plots on the right show the mean psychosis RPSs across 10 deciles plotted against BOLD parameter estimates in the significant clusters identified in the multiple regression. Note that the 10 deciles reflect the data extracted from the clusters within the VS, which remained significant and are purely for illustration purposes. Error bars indicate 95% CI. AU indicates arbitrary units; L, left hemisphere; NS, nonsignificant.

work[15] that suggested that the schizophrenia RPS is associated with altered reward processing in healthy individuals. A previous study[12] suggests that psychosis is characterized by VS hypoactivation, which might relate to negative symptoms that underpin psychosis. However, other studies have suggested that type 2 bipolar disorder and adolescent bipolar disorder are associated with frontostriatal BOLD signal during reward anticipation[47-49] and that relatives of patients with schizophrenia have increased VS BOLD during reward receipt.[19] In line with the meta-analysis,[12] the most prominent association between psychosis RPS and VS BOLD occurred during the reward anticipation phase, suggesting that risk for psychosis may alter disrupt incentive motivation and reward salience. The receipt phase could also be less sensitive to VS activation (because of variable success rates), which could explain the weaker association with the psychosis RPS. One key difference between our study and the studies included in the meta-analysis[12] of patients with psychosis is that our sample had a mean age of 14.5, whereas the mean age of the patients in the meta-analysis was approximately 30 years. This hypothesis is supported by recent evidence supporting an age × VS BOLD interaction in adolescents with genetic risk for schizo-

phrenia, where younger adolescent offspring have increased VS BOLD during the MID task, but older adolescents offspring have attenuated VS BOLD.[50] Genetic risk of psychosis may have different effects on brain physiologic mechanisms across the lifespan and leads to enhanced incentive salience in adolescence, which is attenuated during later stages of neurodevelopment. This finding is supported by a recent meta-analysis[51] that found that, compared with adults, adolescents (mean age, 14.1 years) have increased VS BOLD during reward processing, which is attributed to increased motivated activity during adolescence. The different direction of altered VS BOLD may also be explained by state effects (such as medication and disease chronicity).

Although our data suggest an association between the psychosis RPS and WISC-IV variables, the variance explained was small (approximately 0.2%-0.4%) but comparable to other studies[42-44] between the psychosis RPS and IQ or cognition. Our data further suggest that approximately 0.8% to 1.9% of the variance in VS BOLD may be explained by the psychosis RPS, which is comparable to another intermediate phenotype RPS study.[52] Although the VS BOLD variance explained by the psychosis RPS across the whole sample was small, comparing VS BOLD parameters estimates between the 1st and 10th deciles of the psychosis RPS suggested a moderate effect size (Cohen d = 0.22-0.49). Future studies should take advantage of large genotyped population cohorts to compare intermediate phenotypes for individuals at either end of the RPS distribution.

One limitation of the study is that we did not have negative psychosis symptom measures for the behavioral or imaging genetic sample. Such measures would have proved useful in exploring whether VS BOLD mediates the association between the psychosis RPS and negative symptoms. Currently, it remains unknown whether the putative links among psychopathologic conditions, negative symptoms, and VS BOLD are mediated by common genetic risk factors. Although we found associations between the psychosis RPS and depressive symptoms, these associations were independent of the RPS effects on VS BOLD, suggesting pleiotropic effects of genetic psychosis susceptibility. Future work should explore the role of VS BOLD during reward anticipation as a candidate mechanism by which the psychosis RPS may mediate effects on negative symptoms. Another limitation is that the association between the psychosis RPS and VS BOLD was in the opposite direction of that expected, although this finding is in line with a previous study[50] of VS BOLD and genetic risk for schizophrenia across adolescent development. A previous meta-analysis[12] suggests that psychosis is associated with attenuated BOLD in the VS, which is also linked to negative symptoms. Because we observed increased VS BOLD, the link between psychosis and psychosis symptom expression is less clear. We did not observe any association between the psychosis RPS and impulsivity.[32] This observation provides no evidence of a role in common risk for psychosis in the discounting of larger, future rewards, suggesting that myopic discounting may be a state feature of psychosis. However, these findings may help to identify the precise reward mechanisms that are altered because of increased psychosis risk. We also acknowledge that substance abuse and dependence may be confounders in the study of VS BOLD.

Conclusions

We observed negative associations between performance IQ and the psychosis RPS but not behavioral impulsivity. Consistent with our experimental hypothesis, we found associations between the psychosis RPS and VS BOLD, primarily during reward anticipation. We suggest that psychosis RPS may play a role in shaping the reward response in the adolescent brain, particularly during periods of reward sensitivity and increased incentive motivation. Future follow-up studies will be needed to assess how common genetic risk relates to (1) VS BOLD in the adult brain, (2) whether psychosis RPS affects the effect of VS BOLD on negative symptoms in adulthood, and (3) whether environmental exposure (ie, cannabis use,[53,54] early life stressors[55]) attenuate these effects. Large neuroimaging studies across multiple sites are well powered to determine such effects and determine case-control differences in subcortical volumes[56-58] and facilitate novel gene discovery.[59] These studies will aid in understanding the genetic and environmental neurobiological mechanisms of negative symptoms, which are currently refractory to antipsychotic medication.[60] Future analysis of specific genetic risk pathways will help to elucidate the neurobiological mechanisms that contribute to alterations of reward processing across the psychosis spectrum and across the lifespan.

ARTICLE INFORMATION

Correction: This article was corrected on August 22, 2016, to clarify an author's full surname in the byline.

Submitted for Publication: January 25, 2016; final revision received April 14, 2016; accepted April 16, 2016.

Published Online: July 6, 2016. doi:10.1001/jamapsychiatry.2016.1135.

Author Affiliations: Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, United Kingdom (Lancaster, Linden); Cardiff University Brain Imaging Research Centre, Cardiff University, Cardiff, United Kingdom (Lancaster, Linden); MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff School of Medicine, Cardiff University, Cardiff, United Kingdom (Linden); MRC Integrative Epidemiology Unit, School of Social and Community Medicine, Faculty of Medicine and Dentistry, University of Bristol, Bristol, United Kingdom (Tansey); Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (Banaschewski); Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland (Bokde); University Medical Centre Hamburg-Eppendorf, Hamburg, Germany (Bromberg, Büchel); MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, United Kingdom (Cattrell, Schumann); Department of Psychiatry, Universite de Montreal, CHU Ste Justine Hospital, Montreal, Quebec, Canada (Conrod); Department of Psychological Medicine and Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College, London, United Kingdom (Conrod); Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (Flor); Neurospin, Commissariat à l'Energie Atomique, Paris, France (Frouin, Orfanos); Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (Gallinat); Departments of Psychiatry and Psychology, University of Vermont,

Burlington (Garavan); Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom (Gowland); Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin, Berlin, Germany (Heinz, Walter); Physikalisch-Technische Bundesanstalt, Berlin, Germany (Ittermann); Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1000, Neuroimaging and Psychiatry Research Unit, University Paris-Sud, Orsay, France (Martinot, Paillère Martinot, Artiges, Lemaitre); University Paris Descartes, Sorbonne Paris Cité, Paris, France (Martinot, Paillère Martinot, Lemaitre); Assistance Publique–Hôpitaux de Paris, Maison de Solenn, Cochin Hospital, Paris, France (Paillère Martinot); Orsay Hospital, Orsay, France (Artiges); Rotman Research Institute, Baycrest Health Sciences, and Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario, Canada (Nees, Paus); Department of Child and Adolescent Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Poustka); Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany (Smolka, Vetter, Jurk, Mennigen); Department of Psychology, University College Dublin, Dublin, Ireland (Whelan).

Author Contributions: Dr Lancaster had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Lancaster, Linden, Büchel, Conrod, Flor, Schumann, Gallinat, Garavan, Ittermann, Smolka.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Lancaster, Linden.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Lancaster, Tansey, Frouin.
Obtained funding: Linden, Büchel, Conrod, Gallinat, Ittermann, Martinot, Paillère Martinot, Smolka, Schumann.
Administrative, technical, or material support: Banaschewski, Bokde, Bromberg, Cattrell, Conrod, Gallinat, Gowland, Heinz, Ittermann, Martinot, Orfanos, Smolka, Walter, Whelan.
Study supervision: Garavan, Heinz, Ittermann, Paus, Smolka.

Conflict of Interest Disclosures: Dr Banaschewski reported serving in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford Outcomes, PCM Scientific, Shire, and Viforpharma and receiving conference support or speaker fees from Janssen McNeil, Lilly, Medice, Novartis, and Shire. He also reports being involved in clinical trials conducted by Shire and Viforpharma. The present work is unrelated to these grants and relationships. Dr Gallinat reported receiving research funding from AstraZeneca and speaker fees from Janssen-Cilag and Otsuka. Dr Paillère Martinot reported receiving compensation from Janssen-Cilag for continuing medical education–related activities. Dr Poustka reported receiving conference attendance support or speaker fees from Eli Lilly, Medice, Novartis, and Shire. Dr Walter reported receiving honoraria from Servier UK. No other disclosures were reported.

Funding/Support: This study was funded by the Neuroscience and Mental Health Research Institute; grant LSHM-CT- 2007-037286 from the European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-Related Behaviour in Normal Brain Function and Psychopathology); grants 602450, 602805, and 603016 from FP7 projects IMAGEMEND (Imaging Genetics for Mental Disorders), AGGRESSOTYPE, and MATRICS; grant 115300-2 from the Innovative Medicine Initiative Project EU-AIMS; grants 93558 (Developmental Pathways Into Adolescent Substance Abuse), MR/K004360/1 (Behavioural and Neurophysiological Effects of Schizophrenia Risk Genes: A Multi-locus, Pathway Based Approach), and MR/N000390/1 (Consortium on Vulnerability to Externalizing Disorders and Addictions) from the Medical Research Council; grant G0800509 from the MRC Centre for Neuropsychiatric Genetics and Genomics; the Swedish funding agencies VR, FORTE, and FORMAS; the Medical Research Council and the Wellcome Trust (Behavioural and Clinical Neuroscience Institute, University of Cambridge); the National Institute for Health Research Biomedical Research Centre at South London and Maudsley National Health Services Foundation Trust and King's College London; grants 01GS08152 and 01EV0711 from the Bundesministeriumfür Bildung und Forschung; grant eMED SysAlc01ZX1311A from Forschungsnetz AERIAL; and grants SM 80/7-1, SM 80/7-2, and SFB 940/1 from the Deutsche Forschungsgemeinschaft. Further support was provided by ANR, the Fondation de France, the Fondation pour la Recherche Médicale, the Mission Interministérielle de Lutte-contre-les -Drogues-et-les-Conduites-Addictives, and an interface grant from the Assistance Publique–Hôpitaux de Paris and INSERM, Paris Sud University IDEX 2012, and grant RO1 MH085772-01A1 (Axon, Testosterone, and Mental Health During Adolescence) and consortium grant U54 EB020403 from the National Institutes of Health, supported by a cross–National Institutes of Health alliance that funds big data to knowledge centers of excellence.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

Group Information: The other IMAGEN consortium members include: *King's College, Institute of Psychiatry, London, UK:* G. Schumann, P. Conrod, L. Reed, G. Barker, S. Williams, E. Loth, M. Struve, A. Lourdusamy, S. Costafreda, A. Cattrell, C. Nymberg, L. Topper, L. Smith, S. Havatzias, K. Stueber, C. Mallik, T.-K. Clarke, D. Stacey, C. Peng Wong, H. Werts, S. Williams, C. Andrew, S. Desrivieres, S. Zewdie (Coordination office). *Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité—Universitätsmedizin Berlin, Berlin, Germany:* A. Heinz, J. Gallinat, I. Häke, N. Ivanov, A. Klär, J. Reuter, C. Palafox, C. Hohmann, C. Schilling, K. Lüdemann, A. Romanowski, A. Ströhle, E. Wolff, M. Rapp. *Physikalisch-Technische Bundesanstalt, Berlin, Germany:* B. Ittermann, R. Brühl, A. Ihlenfeld, B. Walaszek, F. Schubert. *Institute of Neuroscience, Trinity College, Dublin, Ireland:* H. Garavan, C. Connolly, J. Jones, E. Lalor, E. McCabe, A. Ní Shiothcháin, R. Whelan. *Department of Psychopharmacology, Central Institute of Mental Health, Mannheim, Germany:* R. Spanagel, F. Leonardi-Essmann, W. Sommer. *Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Mannheim, Germany:* H. Flor, S. Vollstaedt-Klein, F. Nees. *Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, Mannheim, Germany:* T. Banaschewski, L. Poustka, S. Steiner. *Department of Addictive Behaviour and Addiction Medicine, Mannheim, Germany:* K. Mann, M. Buehler, S. Vollstedt-Klein. *Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany:* M. Rietschel, E. Stolzenburg, C. Schmal, F. Schirmbeck. *Brain and Body Centre, University of Nottingham, Nottingham, UK:* T. Paus, P. Gowland, N. Heym, C. Lawrence, C. Newman, Z. Pausova. *Technische Universitaet Dresden, Dresden, Germany:* M. Smolka, T. Huebner, S. Ripke, E. Mennigen, K. Muller, V. Ziesch. *Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany:* C. Büchel, U. Bromberg, T. Fadai, L. Lueken, J. Yacubian, J. Finsterbusch. *Institut National de la Santé et de la Recherche Médicale, Service Hospitalier Frédéric Joliot, Orsay, France:* J.-L. Martinot, E. Artiges, N. Bordas, S. de Bournonville, Z. Bricaud, F. Gollier Briand, H. Lemaitre, J. Massicotte, R. Miranda, M.-L. Paillère Martinot, J. Penttilä. *Neurospin, Commissariat à l'Energie Atomique, Paris, France:* J.-B. Poline, A. Barbot, Y. Schwartz, C. Lalanne, V. Frouin, B. Thyreau. *Department of Experimental Psychology, Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK:* J. Dalley, A. Mar, T. Robbins, N. Subramaniam, D. Theobald, N. Richmond, M. de Rover, A. Molander, E. Jordan, E. Robinson, L. Hipolata, M. Moreno, Mercedes Arroyo. *University of Sussex, Brighton, UK:* D. Stephens, T. Ripley, H. Crombag, Y. Pena. *Centre National de Genotypage, Evry, France (CNG):* M. Lathrop, D. Zelenika, S. Heath. *German Centre for Ethics in Medicine, Bonn (DZEM), Germany:* D. Lanzerath, B. Heinrichs, T. Spranger. *Gesellschaft fuer Ablauforganisation m.b.H. (Munich) (GABO), Germany:* B. Fuchs, C. Speiser. *Klinik für Kinder- und Jugendpsychiatrie, Zentrum für Psychosoziale Medizin, Universitätsklinikum Heidelberg, Germany:* F. Resch, J. Haffner, P. Parzer, R. Brunner. *Scito, Paris, France:* A. Klaassen, I. Klaassen. *PERTIMM, Asnières-Sur-Seine, France:* P. Constant, X. Mignon. *NordicNeuroLabs, Bergen, Norway:* T. Thomsen, S. Zysset, A. Vestboe. *Delosis Ltd, London, UK:* J. Ireland, J. Rogers.

Additional Contributions: Sylvane Desrivieres, MD, played a significant role in data processing and preparation of the material used in the study.

REFERENCES

1. Ruderfer DM, Fanous AH, Ripke S, et al; Schizophrenia Working Group of Psychiatric Genomics Consortium; Bipolar Disorder Working Group of Psychiatric Genomics Consortium; Cross-Disorder Working Group of Psychiatric Genomics Consortium. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry*. 2014;19(9):1017-1024.

2. Lee SH, Ripke S, Neale BM, et al; Cross-Disorder Group of the Psychiatric Genomics Consortium; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet*. 2013;45(9):984-994.

3. Craddock N, O'Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed

(or "schizoaffective") psychoses. *Schizophr Bull*. 2009;35(3):482-490.

4. Hall J, Whalley HC, Marwick K, et al. Hippocampal function in schizophrenia and bipolar disorder. *Psychol Med*. 2010;40(5):761-770.

5. McIntosh AM, Job DE, Moorhead WJ, et al. Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure. *Am J Med Genet B Neuropsychiatr Genet*. 2006;141B(1):76-83.

6. McIntosh AM, Whalley HC, McKirdy J, et al. Prefrontal function and activation in bipolar disorder and schizophrenia. *Am J Psychiatry*. 2008;165(3):378-384.

7. Ziauddeen H, Murray GK. The relevance of reward pathways for schizophrenia. *Curr Opin Psychiatry*. 2010;23(2):91-96.

8. Barch DM, Dowd EC. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. *Schizophr Bull*. 2010;36(5):919-934.

9. Strauss GP, Waltz JA, Gold JM. A review of reward processing and motivational impairment in schizophrenia. *Schizophr Bull*. 2014;40(suppl 2):S107-S116.

10. Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia—psychopathological and behavioral correlates. *Eur Psychiatry*. 2002;17(1):9-16.

11. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. *Neuroimage*. 2006;29(2):409-416.

12. Radua J, Schmidt A, Borgwardt S, et al. Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. *JAMA Psychiatry*. 2015;72(12):1243-1251.

13. Silverman MH, Krueger RF, Iacono WG, Malone SM, Hunt RH, Thomas KM. Quantifying familial influences on brain activation during the monetary incentive delay task: an adolescent monozygotic twin study. *Biol Psychol*. 2014;103:7-14.

14. Grimm O, Heinz A, Walter H, et al. Striatal response to reward anticipation: evidence for a systems-level intermediate phenotype for schizophrenia. *JAMA Psychiatry*. 2014;71(5):531-539.

15. Lancaster TM, Ihssen N, Brindley LM, et al. Associations between polygenic risk for schizophrenia and brain function during probabilistic learning in healthy individuals. *Hum Brain Mapp*. 2016;37(2):491-500.

16. Schlagenhauf F, Huys QJ, Deserno L, et al. Striatal dysfunction during reversal learning in unmedicated schizophrenia patients. *Neuroimage*. 2014;89:171-180.

17. Rausch F, Mier D, Eifler S, et al. Reduced activation in ventral striatum and ventral tegmental area during probabilistic decision-making in schizophrenia. *Schizophr Res*. 2014;156(2-3):143-149.

18. Rausch F, Mier D, Eifler S, et al. Reduced activation in the ventral striatum during probabilistic decision-making in patients in an at-risk mental state. *J Psychiatry Neurosci*. 2015;40(3):163-173.

19. de Leeuw M, Kahn RS, Vink M. Fronto-striatal dysfunction during reward processing in unaffected siblings of schizophrenia patients. *Schizophr Bull*. 2015;41(1):94-103.

20. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. *J Neurosci*. 2001;21(16):RC159.

21. Nymberg C, Banaschewski T, Bokde AL, et al; IMAGEN consortium. DRD2/ANKK1 polymorphism modulates the effect of ventral striatal activation on working memory performance. *Neuropsychopharmacology*. 2014;39(10):2357-2365.

22. Heekeren HR, Wartenburger I, Marschner A, Mell T, Villringer A, Reischies FM. Role of ventral striatum in reward-based decision making. *Neuroreport*. 2007;18(10):951-955.

23. Schumann G, Loth E, Banaschewski T, et al; IMAGEN consortium. The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. *Mol Psychiatry*. 2010;15(12):1128-1139.

24. Caseras X, Tansey KE, Foley S, Linden D. Association between genetic risk scoring for schizophrenia and bipolar disorder with regional subcortical volumes. *Transl Psychiatry*. 2015;5:e692.

25. Wechsler DL. *Wechsler Intelligence Scale for Children*. 4th ed. San Antonio, TX: The Psychological Corporation; 2004.

26. Kirby KN, Maraković NN. Delay-discounting probabilistic rewards: Rates decrease as amounts increase. *Psychon Bull Rev*. 1996;3(1):100-104.

27. Anokhin AP, Grant JD, Mulligan RC, Heath AC. The genetics of impulsivity: evidence for the heritability of delay discounting. *Biol Psychiatry*. 2015;77(10):887-894.

28. Ahn WY, Rass O, Fridberg DJ, et al. Temporal discounting of rewards in patients with bipolar disorder and schizophrenia. *J Abnorm Psychol*. 2011;120(4):911-921.

29. Heerey EA, Robinson BM, McMahon RP, Gold JM. Delay discounting in schizophrenia. *Cogn Neuropsychiatry*. 2007;12(3):213-221.

30. Purcell SM, Wray NR, Stone JL, et al; International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460(7256):748-752.

31. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet*. 2013;381(9875):1371-1379.

32. Kirby KN, Marakovic NN. Modeling myopic decisions: evidence for hyperbolic delay-discounting within-subjects and amounts. *Organ Behav Hum*. 1995;64(1):22-30.

33. Stringaris A, Vidal-Ribas Belil P, Artiges E, et al; IMAGEN Consortium. The brain's response to reward anticipation and depression in adolescence: dimensionality, specificity, and longitudinal predictions in a community-based sample. *Am J Psychiatry*. 2015;172(12):1215-1223.

34. Peters J, Bromberg U, Schneider S, et al; IMAGEN Consortium. Lower ventral striatal activation during reward anticipation in adolescent smokers. *Am J Psychiatry*. 2011;168(5):540-549.

35. Goodman A, Heiervang E, Collishaw S, Goodman R. The 'DAWBA bands' as an ordered-categorical measure of child mental health: description and validation in British and Norwegian samples. *Soc Psychiatry Psychiatr Epidemiol*. 2011;46(6):521-532.

36. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119-1127.

37. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D. Dissociation of reward anticipation and outcome with event-related fMRI. *Neuroreport*. 2001;12(17):3683-3687.

38. Schneider S, Peters J, Bromberg U, et al; IMAGEN Consortium. Risk taking and the adolescent reward system: a potential common link to substance abuse. *Am J Psychiatry*. 2012;169(1):39-46.

39. Dudbridge F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet*. 2013;9(3):e1003348.

40. Thornton T, Conomos MP, Sverdlov S, et al. Estimating and adjusting for ancestry admixture in statistical methods for relatedness inference, heritability estimation, and association testing. *BMC Proc*. 2014;8(suppl 1):S5.

41. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427.

42. Lencz T, Knowles E, Davies G, et al. Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT). *Mol Psychiatry*. 2014;19(2):168-174.

43. Hatzimanolis A, Bhatnagar P, Moes A, et al. Common genetic variation and schizophrenia polygenic risk influence neurocognitive performance in young adulthood. *Am J Med Genet B Neuropsychiatr Genet*. 2015;168B(5):392-401.

44. Hubbard L, Tansey KE, Rai D, et al. Evidence of common genetic overlap between schizophrenia and cognition. *Schizophr Bull*. 2016;42(3):832-842.

45. Heinrich A, Lourdusamy A, Tzschoppe J, et al; IMAGEN consortium. The risk variant in ODZ4 for bipolar disorder impacts on amygdala activation during reward processing. *Bipolar Disord*. 2013;15(4):440-445.

46. Lancaster TM, Heerey EA, Mantripragada K, Linden DE. CACNA1C risk variant affects reward responsiveness in healthy individuals. *Transl Psychiatry*. 2014;4:e461.

47. Dickstein DP, Finger EC, Skup M, Pine DS, Blair JR, Leibenluft E. Altered neural function in pediatric bipolar disorder during reversal learning. *Bipolar Disord*. 2010;12(7):707-719.

48. Caseras X, Lawrence NS, Murphy K, Wise RG, Phillips ML. Ventral striatum activity in response to reward: differences between bipolar I and II disorders. *Am J Psychiatry*. 2013;170(5):533-541.

49. Singh MK, Kelley RG, Howe ME, Reiss AL, Gotlib IH, Chang KD. Reward processing in healthy offspring of parents with bipolar disorder. *JAMA Psychiatry*. 2014;71(10):1148-1156.

50. Vink M, de Leeuw M, Pouwels R, van den Munkhof HE, Kahn RS, Hillegers M. Diminishing striatal activation across adolescent development during reward anticipation in offspring of schizophrenia patients. *Schizophr Res*. 2016;170(1):73-79.

51. Silverman MH, Jedd K, Luciana M. Neural networks involved in adolescent reward

processing: an activation likelihood estimation meta-analysis of functional neuroimaging studies. *Neuroimage*. 2015;122:427-439.

52. Roussos P, Giakoumaki SG, Zouraraki C, et al. The relationship of common risk variants and polygenic risk for schizophrenia to sensorimotor gating [published online June 27, 2015]. *Biol Psychiatry*. 2015;S0006-3223(15)00526-0. doi:10.1016/j.biopsych.2015.06.019.

53. French L, Gray C, Leonard G, et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. *JAMA Psychiatry*. 2015;72(10):1002-1011.

54. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. *Neuroimage*. 2010;49(1):1133-1143.

55. Corral-Frías NS, Nikolova YS, Michalski LJ, Baranger DA, Hariri AR, Bogdan R. Stress-related anhedonia is associated with ventral striatum reactivity to reward and transdiagnostic psychiatric symptomatology. *Psychol Med*. 2015;45(12):2605-2617.

56. Schmaal L, Veltman DJ, van Erp TG, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. [published online June 30, 2015]. *Mol Psychiatry*. 2016;21(6):806-812. doi:10.1038/mp.2015.69.

57. van Erp TG, Hibar DP, Rasmussen JM, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol Psychiatry*. 2016;21(4):547-553.

58. Hibar DP, Westlye LT, van Erp TG, et al. Subcortical volumetric abnormalities in bipolar disorder [published online February 9, 2016]. *Mol Psychiatry*. doi:10.1038/mp.2015.227.

59. Hibar DP, Stein JL, Renteria ME, et al; Alzheimer's Disease Neuroimaging Initiative; CHARGE Consortium; EPIGEN; IMAGEN; SYS. Common genetic variants influence human subcortical brain structures. *Nature*. 2015;520(7546):224-229.

60. Goghari VM, Sponheim SR, MacDonald AW III. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. *Neurosci Biobehav Rev*. 2010;34(3):468-486.